Compare
MassChallenge vs Techstars
What MassChallenge and Techstars each invest, the equity they take, who they suit and when applications close, from each programme's own pages.
MassChallenge vs Techstars
MassChallenge
- Funding
- not published No upfront investment or funding; MassChallenge describes a competition-based model with cash awards in some programmes
- Instrument
- No investment
- Equity taken
- None (equity-free)
- Programme fee
- No fee No programme or application fee; travel to in-person events is self-funded and no stipends are provided
- Duration
- not published
- Cohort size
- not published
- Cohorts
- not published
- Delivery
- Hybrid
- Stages
- Pre-seed, seed, post-seed
- Sectors
- Health tech, Biotech, Medtech, Cybersecurity
- Open to founders from
- Anywhere
- Perks
-
- Direct access to enterprise, government and defence decision-makers
- Go-to-market, strategy and investor-readiness support
- Pilot, partnership and contract opportunities
The 2026 Security & Resiliency Traction programme runs over 10 weeks for pre-seed to Series A+ companies. The inaugural 2026 Healthcare & Life Sciences Traction cohort had 41 startups.
Techstars
- Funding
- US$220,000 US$220k: $20k on a post-money convertible equity agreement for 5% in common stock plus $200k on an uncapped MFN SAFE
- Instrument
- SAFE
- Equity taken
- 5% 5% in common stock from the convertible equity agreement, plus whatever the $200k uncapped MFN SAFE converts into at the next priced round
- Programme fee
- not published
- Duration
- not published
- Cohort size
- not published
- Cohorts
- not published
- Delivery
- Hybrid
- Stages
- Pre-seed, seed
- Sectors
- Sector-agnostic
- Open to founders from
- not published
- Perks
- not published
Programmes last three months. The New York City programme meets in person for its first two weeks, one week in the middle and demo day. The offer is regional: Techstars Tokyo invests US$120k ($100k uncapped MFN SAFE or J-KISS plus $20k for 5%).
Where they differ
| Term | MassChallenge | Techstars |
|---|---|---|
| Funding | not published | US$220,000 |
| Equity taken | None (equity-free) | 5% |
| Instrument | No investment | SAFE |
| Programme fee | No fee | not published |
| Duration | not published | not published |
| Cohorts | not published | not published |
| Delivery | Hybrid | Hybrid |
| Stages | Pre-seed, seed, post-seed | Pre-seed, seed |
| Sectors | Health tech, Biotech, Medtech, Cybersecurity | Sector-agnostic |
| Based in | Boston, United States | United States |
| Next deadline | not published | 18 November 2026 |
Which fits whom
MassChallenge fits founders
- At the pre-seed, seed or post-seed stage
- Who can join some sessions in person in Boston
- Working in health tech, biotech, medtech or cybersecurity
- Who want to keep all their equity
Techstars fits founders
- At the pre-seed or seed stage
- Who can join some sessions in person in the United States
- In any sector
- Willing to give up 5% equity; the standard offer is US$220,000
Application dates
MassChallenge
Dates not published. The 2026 Security & Resiliency Traction cohort (applications 11 June to 9 July 2026) kicked off in Boston in September 2026. MassChallenge says 2027 Healthcare & Life Sciences Traction applications will be announced.
Techstars
New York City, Boston, London and Anywhere 2027: applications opened 24 August 2026 and close 18 November 2026; the programme starts 8 March 2027 and demo day is 3 June 2027.
MassChallenge vs Techstars: questions founders ask
Which invests more, MassChallenge or Techstars?
Techstars publishes a standard offer of US$220,000; MassChallenge does not publish one.
Which takes less equity, MassChallenge or Techstars?
MassChallenge publishes the smaller stake: MassChallenge none (equity-free), Techstars 5%. Each listing's equity note says what else converts later.
Which closes first, MassChallenge or Techstars?
Techstars closes on 18 November 2026; MassChallenge has no published deadline ahead.
Run a programme? List it free
Send us your dates and terms and we will publish them with a link to your own pages.